Clinical trials: sponsored by Sichuan University
Esophageal Cancer
Comparison of Nab-Paclitaxel Versus Paclitaxel in Neoadjuvant Immunochemotherapy Therapy for Esophageal Squamous Cell Carcinoma: A Retrospective IPTW-Adjusted Analysis
Taxane-based agents are widely used in the treatment of esophageal squamous cell carcinoma (ESCC). Among these, nab-paclitaxel (albumin-bound paclitaxel) and paclitaxel are the most commonly used.
- Trial name
- NCT07549269
- Testing
- The cohort included 161 patients treated with solvent-based paclitaxel and 226 treated with nanoparticle albumin-bound paclitaxel.
- Where
- 3 sites in China
- Volunteers
- 387 people
- Sponsor
- Sichuan University
Neuroblastoma (NB)
Safety, Tolerability, and Preliminary Efficacy of [211At]MABG in Patients With Relapsed or Refractory Neuroblastoma
Fractionated dosing of [211At]MABG Radiotherapy in Relapsed/Refractory Neuroblastoma
- Trial name
- NCT07767630
- Testing
- [211At]MABG
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Sichuan University
Malignant Peritoneal Effusion, Malignant Ascites
Dual-targeting VEGFR1 and PD-L1 CAR-T for Pleural, Peritoneal, or Leptomeningeal Metastases
This is a Phase I, open-label, single-arm, dose-escalation and expansion study designed to evaluate the safety, tolerability, and preliminary antitumor activity of dual-targeting VEGFR1/PD-L1 chimeric antigen receptor (CAR)…
- Conditions
- Malignant Peritoneal Effusion, Malignant Ascites, Serous Cavity Metastatises, Leptomeningeal Metastases
- Trial name
- NCT05477927
- Testing
- Dual-targeting VEGFR1/PD-L1 CAR-T cells
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Sichuan University
Esophageal Squamous Cell Carcinoma
Survival Prediction After Neoadjuvant Chemoimmunotherapy and Esophagectomy for Esophageal Squamous Cell Carcinoma
The goal of this retrospective observational study is to develop and internally evaluate a prognostic model for overall survival in patients with esophageal squamous cell carcinoma who received neoadjuvant chemoimmunotherapy…
- Trial name
- NCT07488624
- Where
- 3 sites in China
- Volunteers
- 414 people
- Sponsor
- Sichuan University
Non-Small Cell Lung Cancer, Adjuvant Therapy
Adjuvant Immune Checkpoint Inhibitor Versus Observation After Neoadjuvant Immunochemotherapy and Surgery in High-Risk NSCLC
This multicenter, randomized, open-label, phase II trial is designed to evaluate the efficacy and safety of adjuvant sintilimab in patients with completely resected non-small cell lung cancer who remain at high risk of recurrence…
- Conditions
- Non-Small Cell Lung Cancer, Adjuvant Therapy, Immune Checkpoint Inhibitors
- Trial name
- RICA (NCT07748325)
- Testing
- Sintilimab
- Where
- 2 sites in China
- Volunteers
- 100 people
- Sponsor
- Sichuan University
Small Cell Lung Cancer Extensive Stage
Phase I Clinical Study of α-PD-L1/DLL3 CAR-T in Patients With R/R SCLC
A study to evaluate the safety and feasibility of α-PD-L1/4-1BB DLL3 Chimeric Antigen Receptor (CAR)-T (BHP01) in patients with Relapsed/Refractory Small Cell Lung Cancer (SCLC) and determine the appropriate CAR-T cell dose.
- Trial name
- NCT06348797
- Testing
- α-PD-L1/4-1BB DLL3 CAR-T (BHP01)
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Sichuan University
NSCLC
A Phase Ib Study of Tislelizumab Plus SYS6010 in Immunotherapy-Pretreated Locally Advanced or Metastatic NSCLC
Introduction: Patients with driver gene-negative non-small cell lung cancer (NSCLC) who experience treatment failure following immune checkpoint inhibitor (ICI) therapy have limited subsequent treatment options, representing an…
- Trial name
- SYS6010 (NCT07692048)
- Testing
- SYS6010
- Where
- China
- Volunteers
- 21 people
- Sponsor
- Sichuan University
Radiotherapy, Immune Checkpoint Inhibitors (ICIs)
Real-world Study on the Efficacy, Safety, and Prognostic Factors of Immune Checkpoint Inhibitors Combined With Radiotherapy in Patients With Malignant Tumors: A Prospective Non-interventional Clinical Study
Currently, chemotherapy, targeted therapy, immunotherapy, and radiotherapy are the core treatment modalities for malignant tumors, with technologies advancing rapidly.
- Trial name
- NCT07665736
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Sichuan University
Neoplasms, Drug Therapy
Analysis of Efficacy and Outcomes of Immunotherapy for Malignant Tumors: A Prospective Non-interventional Clinical Study
The population receiving immunotherapy is heterogeneous. Multiple factors, including combination treatment modalities, influence the immune response, and survival outcomes also vary among individuals receiving immunotherapy.
- Conditions
- Neoplasms, Drug Therapy, Immune Checkpoint Inhibitors (ICIs)
- Trial name
- NCT07665697
- Where
- China
- Volunteers
- 500 people
- Sponsor
- Sichuan University
Gastric Adenocarcinoma, Esophagogastric Junction Adenocarcinoma
Perioperative Fruquintinib Combined With Sintilimab and SOX for Locally Advanced Gastric or GEJ Adenocarcinoma
The purpose of this clinical trial is to evaluate whether perioperative fruquintinib combined with sintilimab and SOX is effective in treating locally advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma.
- Trial name
- NCT07658872
- Testing
- fruquintinib + sintilimab + SOX, Sinitilimab+SOX
- Volunteers
- 120 people
- Sponsor
- Sichuan University
Advanced Pancreatic Adenocarcinoma
Peptide Nanovaccine (ONVAX-01) Plus Anti-PD-1 Antibody and Chemotherapy in Advanced Pancreatic Cancer
The goal of this clinical trial is to evaluate the safety and preliminary effectiveness of a new combination therapy in patients with advanced pancreatic cancer. The main questions it aims to answer are: 1.
- Trial name
- NCT07637786
- Testing
- ONVAX-01 plus Anti-PD-1 and Chemotherapy
- Where
- China
- Volunteers
- 9 people
- Sponsor
- Sichuan University
NSCLC, Low Dose Radiotherapy
Safety and Tolerability of Low Dose Radiotherapy Concurrent SBRT and PD-1 Inhibitors in Advanced NSCLC.
This pilot phase I trial aims to investigate the safety and tolerability of low dose radiotherapy (LDRT) and concurrent partial stereotactic body radiation therapy (SBRT) in combination with programmed cell death-1 (PD-1)…
- Conditions
- NSCLC, Low Dose Radiotherapy, Stereotactic Body Radiotherapy, PD-1 Inhibitor
- Trial name
- NCT05615142
- Testing
- Low Dose Radiotherapy, stereotactic body radiation therapy, PD-1 Inhibitors
- Where
- China
- Volunteers
- 9 people
- Sponsor
- Sichuan University
NSCLC, Low Dose Radiotherapy
Safety and Efficacy of Whole Brain LDRT+ICI+Intrathecal Chemotherapy in Refractory Meningeal Metastasis of Lung Cancer
This phase I study aims to investigate the safety and efficacy of whole brain low dose radiotherapy (WB-LDRT) combined with ICI and intrathecal chemotherapy for treatment of refractory meningeal metastasis of lung cancer.
- Conditions
- NSCLC, Low Dose Radiotherapy, PD-1 Inhibitor, Leptomeningeal Metastasis
- Trial name
- NCT06431685
- Testing
- Whole Brain Low Dose Radiotherapy, Pemetrexed, Sintilimab
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Sichuan University
Non Small Cell Lung Cancer
Sunvozertinib Combined With Chemotherapy for EGFRm After EGFR-TKI Treatment Failure：Phase I/II
To access the anti-tumor efficacy, safety and tolerability of Sunvozertinib combined with chemotherapy in patients with locally advanced or metastatic non-small-cell lung cancer (NSCLC) harboring epidermal growth factor receptor…
- Trial name
- WU-KONG36 (NCT06195189)
- Testing
- Sunvozertinib, Chemotherapy
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Sichuan University
Lung Cancer (SCLC)
Safety and Efficacy of Radiotherapy Combined With Immunochemotherapy in Pre-treated SCLC Patients With Liver Metastases
This is clinical trial evaluating the safety and efficacy of radiotherapy combined with immunotherapy and chemotherapy in patients with extensive-stage small-cell lung cancer (ES-SCLC) and liver metastases.
- Trial name
- NCT07258147
- Testing
- Immunotherapy, Chemotherapy (Etoposide, Nab-paclitaxel, Irinotecan, or Lurbinectedin), low-dose radiation
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Sichuan University
Lung Cancer, Extensive-stage Small-cell Lung Cancer
Safety and Tolerability of LDRT+Sugemalimab+Chemotherapy+Olaparib for First-Line Treatment of SLFN-11 Positive ES-SCLC
The purpose of this study was to evaluate the safety and efficacy of low-dose radiotherapy (LDRT) combined with sugemalimab, olaparib, chemotherapy in the first-line treatment of SLFN-11 positive extensive stage small cell lung…
- Trial name
- NCT06217757
- Testing
- Low-dose radiotherapy, Etoposide, Cisplatin
- Where
- China
- Volunteers
- 45 people
- Sponsor
- Sichuan University
Solid Tumor
Safety and Tolerability of LDRT Plus Concurrent Partial SBRT and Tislelizumab in Patients With Bulky Tumors
This is a 3+3 dose escalation phase I study which aims to evaluate the safety and tolerability of low dose radiotherapy (LDRT) plus concurrent partial Stereotactic Ablative Radiotherapy (SBRT) and Tislelizumab in Patients with…
- Trial name
- NCT06349837
- Testing
- Tislelizumab, Low Dose Radiotherapy, Stereotactic Ablative Radiotherapy
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Sichuan University
SCLC, Extensive Stage
Phase 1b/2 Study of LDRT in Combination With AK104 Plus Chemotherapy as First-line Treatment for ES-SCLC
Phase Ib/II, open-label, multicentre study to evaluate the efficacy and safety of low-dose radiotherapy (LDRT) combined with AK104 and chemotherapy as first-line treatment for patients with ES-SCLC.
- Trial name
- NCT06477523
- Testing
- AK104, Etoposide, Carboplatin
- Where
- 2 sites in China
- Volunteers
- 57 people
- Sponsor
- Sichuan University
Extensive-stage Small-cell Lung Cancer
Study of Low-Dose Radiotherapy Concurrent Chemotherapy With Serplulimab for Patients With ES-SCLC
This is a Phase II, single arm, multicenter study designed to evaluate the safety and efficacy of low-dose radiotherapy (LDRT) concurrent cisplatin/carboplatin plus etoposide with serplulimab in participants who have…
- Trial name
- NCT05765825
- Testing
- serplulimab, Cisplatin, Carboplatin
- Where
- 8 sites in China
- Volunteers
- 61 people
- Sponsor
- Sichuan University
Extensive-stage Small-cell Lung Cancer
Low-dose Radiotherapy Combined With Concurrent Chemotherapy, Toripalimab and Tifcemalimab in the Treatment of ES-SCLC
To evaluate the tolerability and safety of Low-dose radiotherapy combined with concurrent Chemotherapy, Toripalimab and Tifcemalimab in first-line treatment of Extensive-Stage Small Cell Lung Cancer, and to determine the RP2D.
- Trial name
- NCT06732258
- Testing
- Low-dose radiotherapy, Tifcemalimab injection, Toripalimab
- Sponsor
- Sichuan University